{"transactions":[{"id":670895,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:38:50.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":false,"shares":679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":113734,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":679},"source":{"system":"sec-edgar","filing":"0001918845-26-000031","document":"form4-09012026_080946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000031/form4-09012026_080946.xml","form_type":"4"}},{"id":670894,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-01T20:38:50.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":679,"price":20,"value":13580.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000031","document":"form4-09012026_080946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000031/form4-09012026_080946.xml","form_type":"4"}},{"id":670893,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-01T20:38:50.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":true,"shares":679,"price":8.04,"value":5459.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":52455,"source":{"system":"sec-edgar","filing":"0001918845-26-000031","document":"form4-09012026_080946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000031/form4-09012026_080946.xml","form_type":"4"}},{"id":681053,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T20:10:15.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":123750,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001918845-26-000029","document":"form4-08192026_040810.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000029/form4-08192026_040810.xml","form_type":"4"}},{"id":681052,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:15.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":20,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000029","document":"form4-08192026_040810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000029/form4-08192026_040810.xml","form_type":"4"}},{"id":681051,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:15.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":1000,"price":12.65,"value":12650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":52776,"source":{"system":"sec-edgar","filing":"0001918845-26-000029","document":"form4-08192026_040810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000029/form4-08192026_040810.xml","form_type":"4"}},{"id":689000,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-12T20:10:11.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":114413,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":679},"source":{"system":"sec-edgar","filing":"0001918845-26-000026","document":"form4-08122026_040801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000026/form4-08122026_040801.xml","form_type":"4"}},{"id":688999,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:10:11.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":679,"price":20,"value":13580.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000026","document":"form4-08122026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000026/form4-08122026_040801.xml","form_type":"4"}},{"id":688998,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:10:11.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":679,"price":8.04,"value":5459.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":52455,"source":{"system":"sec-edgar","filing":"0001918845-26-000026","document":"form4-08122026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000026/form4-08122026_040801.xml","form_type":"4"}},{"id":701355,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-29T20:05:05.000Z","date":"2026-07-27","kind":"exercise","planned":true,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":124750,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001918845-26-000024","document":"form4-07292026_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000024/form4-07292026_040701.xml","form_type":"4"}},{"id":701354,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-29T20:05:05.000Z","date":"2026-07-27","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":20,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000024","document":"form4-07292026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000024/form4-07292026_040701.xml","form_type":"4"}},{"id":701353,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-29T20:05:05.000Z","date":"2026-07-27","kind":"exercise","planned":true,"acquired":true,"shares":1000,"price":12.65,"value":12650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":52776,"source":{"system":"sec-edgar","filing":"0001918845-26-000024","document":"form4-07292026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000024/form4-07292026_040701.xml","form_type":"4"}},{"id":717308,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:05:31.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":1779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":115092,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":1779},"source":{"system":"sec-edgar","filing":"0001918845-26-000022","document":"form4-07022026_040722.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000022/form4-07022026_040722.xml","form_type":"4"}},{"id":717307,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:05:31.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":2875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":125750,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":2875},"source":{"system":"sec-edgar","filing":"0001918845-26-000022","document":"form4-07022026_040722.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000022/form4-07022026_040722.xml","form_type":"4"}},{"id":717306,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:05:31.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":4654,"price":20,"value":93080.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000022","document":"form4-07022026_040722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000022/form4-07022026_040722.xml","form_type":"4"}},{"id":717305,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:05:31.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":1779,"price":8.04,"value":14303.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":56430,"source":{"system":"sec-edgar","filing":"0001918845-26-000022","document":"form4-07022026_040722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000022/form4-07022026_040722.xml","form_type":"4"}},{"id":717304,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:05:31.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":2875,"price":12.65,"value":36368.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":54651,"source":{"system":"sec-edgar","filing":"0001918845-26-000022","document":"form4-07022026_040722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000022/form4-07022026_040722.xml","form_type":"4"}},{"id":726215,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T21:24:52.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":1450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":116871,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":1450},"source":{"system":"sec-edgar","filing":"0001918845-26-000020","document":"form4-06252026_090648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000020/form4-06252026_090648.xml","form_type":"4"}},{"id":726214,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T21:24:52.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":1450,"price":18,"value":26100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000020","document":"form4-06252026_090648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000020/form4-06252026_090648.xml","form_type":"4"}},{"id":726213,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T21:24:52.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":1450,"price":8.04,"value":11658.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":53226,"source":{"system":"sec-edgar","filing":"0001918845-26-000020","document":"form4-06252026_090648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000020/form4-06252026_090648.xml","form_type":"4"}},{"id":731565,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:00:05.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":21781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date."}],"balance_after":21781,"derivative":{"exercise_price":13.55,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":21781},"source":{"system":"sec-edgar","filing":"0001193125-26-276054","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526276054/ownership.xml","form_type":"4"}},{"id":739266,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-12T20:26:49.000Z","date":"2026-06-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":1084,"price":13.1,"value":14200.4,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,738 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000018","document":"form4-06122026_080645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000018/form4-06122026_080645.xml","form_type":"4"}},{"id":756754,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T20:05:22.000Z","date":"2026-05-28","kind":"exercise","planned":true,"acquired":false,"shares":679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":118321,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":679},"source":{"system":"sec-edgar","filing":"0001918845-26-000016","document":"form4-06012026_040618.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000016/form4-06012026_040618.xml","form_type":"4"}},{"id":756753,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-01T20:05:22.000Z","date":"2026-05-28","kind":"sale","planned":true,"acquired":false,"shares":679,"price":16,"value":10864.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":47122,"source":{"system":"sec-edgar","filing":"0001918845-26-000016","document":"form4-06012026_040618.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000016/form4-06012026_040618.xml","form_type":"4"}},{"id":756752,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-01T20:05:22.000Z","date":"2026-05-28","kind":"exercise","planned":true,"acquired":true,"shares":679,"price":8.04,"value":5459.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":47801,"source":{"system":"sec-edgar","filing":"0001918845-26-000016","document":"form4-06012026_040618.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000016/form4-06012026_040618.xml","form_type":"4"}},{"id":763303,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:10:10.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":43500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents performance stock units (\"PSUs\") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":47122,"source":{"system":"sec-edgar","filing":"0001918845-26-000014","document":"form4-05262026_040503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000014/form4-05262026_040503.xml","form_type":"4"}},{"id":771355,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-19T20:10:08.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":128625,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001918845-26-000012","document":"form4-05192026_040503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000012/form4-05192026_040503.xml","form_type":"4"}},{"id":771354,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-19T20:10:08.000Z","date":"2026-05-15","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":18.76,"value":56280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":3622,"source":{"system":"sec-edgar","filing":"0001918845-26-000012","document":"form4-05192026_040503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000012/form4-05192026_040503.xml","form_type":"4"}},{"id":771353,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-19T20:10:08.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":true,"shares":3000,"price":12.65,"value":37950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":6622,"source":{"system":"sec-edgar","filing":"0001918845-26-000012","document":"form4-05192026_040503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000012/form4-05192026_040503.xml","form_type":"4"}},{"id":788292,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":false,"shares":28650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":119000,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":28650},"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788291,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":false,"shares":77905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":131625,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":77905},"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788290,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-05","kind":"exercise","planned":true,"acquired":false,"shares":679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":147650,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":679},"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788289,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-05","kind":"exercise","planned":true,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":209530,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788288,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":10058,"price":22.88,"value":230127.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":3622,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788287,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":19015,"price":22.406,"value":426050.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported securities were sold in multiple transactions at prices ranging from $21.83 to $22.80. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":13680,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788286,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":44944,"price":21.1968,"value":952668.9792,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":32695,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788285,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":19.6502,"value":98251.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were sold in multiple transactions at prices ranging from $19.08 to $19.99. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":77639,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788284,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":27538,"price":18.0262,"value":496405.4956,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":82639,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788283,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":true,"shares":28650,"price":8.04,"value":230346.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":110177,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788282,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":true,"shares":77905,"price":12.65,"value":985498.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":81527,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788281,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":1679,"price":16,"value":26864.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":3622,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788280,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-05","kind":"exercise","planned":true,"acquired":true,"shares":679,"price":8.04,"value":5459.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":5301,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788279,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-05","kind":"exercise","planned":true,"acquired":true,"shares":1000,"price":12.65,"value":12650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":4622,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":812330,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-08T20:51:43.000Z","date":"2026-04-06","kind":"exercise","planned":true,"acquired":false,"shares":3970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":210530,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":3970},"source":{"system":"sec-edgar","filing":"0001918845-26-000008","document":"form4-04082026_080437.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000008/form4-04082026_080437.xml","form_type":"4"}},{"id":812329,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-08T20:51:43.000Z","date":"2026-04-06","kind":"sale","planned":true,"acquired":false,"shares":3970,"price":18.0122,"value":71508.434,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":3622,"source":{"system":"sec-edgar","filing":"0001918845-26-000008","document":"form4-04082026_080437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000008/form4-04082026_080437.xml","form_type":"4"}},{"id":812328,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-08T20:51:43.000Z","date":"2026-04-06","kind":"exercise","planned":true,"acquired":true,"shares":3970,"price":12.65,"value":50220.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":7592,"source":{"system":"sec-edgar","filing":"0001918845-26-000008","document":"form4-04082026_080437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000008/form4-04082026_080437.xml","form_type":"4"}},{"id":815750,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T19:13:22.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":148329,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":679},"source":{"system":"sec-edgar","filing":"0001918845-26-000006","document":"form4-04032026_070418.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000006/form4-04032026_070418.xml","form_type":"4"}},{"id":815749,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-03T19:13:22.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":679,"price":16,"value":10864.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":3622,"source":{"system":"sec-edgar","filing":"0001918845-26-000006","document":"form4-04032026_070418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000006/form4-04032026_070418.xml","form_type":"4"}},{"id":815748,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-03T19:13:22.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":679,"price":8.04,"value":5459.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":4301,"source":{"system":"sec-edgar","filing":"0001918845-26-000006","document":"form4-04032026_070418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000006/form4-04032026_070418.xml","form_type":"4"}},{"id":834576,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-18T20:07:19.000Z","date":"2026-03-16","kind":"exercise","planned":true,"acquired":false,"shares":5992,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":149008,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":5992},"source":{"system":"sec-edgar","filing":"0001918845-26-000004","document":"form4-03182026_080310.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000004/form4-03182026_080310.xml","form_type":"4"}},{"id":834575,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-18T20:07:19.000Z","date":"2026-03-16","kind":"exercise","planned":true,"acquired":false,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":214500,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001918845-26-000004","document":"form4-03182026_080310.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000004/form4-03182026_080310.xml","form_type":"4"}},{"id":834574,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-18T20:07:19.000Z","date":"2026-03-16","kind":"sale","planned":true,"acquired":false,"shares":25492,"price":16.1465,"value":411606.578,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were sold in multiple transactions at prices ranging from $16.00 to $16.34. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":3622,"source":{"system":"sec-edgar","filing":"0001918845-26-000004","document":"form4-03182026_080310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000004/form4-03182026_080310.xml","form_type":"4"}},{"id":834573,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-18T20:07:19.000Z","date":"2026-03-16","kind":"exercise","planned":true,"acquired":true,"shares":5992,"price":8.04,"value":48175.68,"ownership":{"direct":true},"balance_after":29114,"source":{"system":"sec-edgar","filing":"0001918845-26-000004","document":"form4-03182026_080310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000004/form4-03182026_080310.xml","form_type":"4"}},{"id":834572,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-18T20:07:19.000Z","date":"2026-03-16","kind":"exercise","planned":true,"acquired":true,"shares":19500,"price":12.65,"value":246675.0,"ownership":{"direct":true},"balance_after":23122,"source":{"system":"sec-edgar","filing":"0001918845-26-000004","document":"form4-03182026_080310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000004/form4-03182026_080310.xml","form_type":"4"}},{"id":873591,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T21:23:06.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":105000,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001918845-26-000002","document":"form4-03022026_090303.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000002/form4-03022026_090303.xml","form_type":"4"}},{"id":970777,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-12T21:18:52.000Z","date":"2025-12-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":1013,"price":4.1,"value":4153.3,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,622 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction."}],"balance_after":3622,"source":{"system":"sec-edgar","filing":"0001470831-25-000412","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000147083125000412/form4.xml","form_type":"4"}},{"id":1071030,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-08T21:30:07.000Z","date":"2025-08-07","kind":"grant","planned":false,"acquired":true,"shares":79456,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 79,456 shares of the Issuer's common stock, which shall vest as to one-third of the shares underlying the option on each of the first, second and third anniversaries of the grant date of the award, subject to the Reporting Person's continued service as a director on each such vesting date."}],"balance_after":79456,"derivative":{"exercise_price":7.03,"expiration_date":"2035-08-07","underlying":"Common Stock","underlying_shares":79456},"source":{"system":"sec-edgar","filing":"0000950170-25-106028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017025106028/ownership.xml","form_type":"4"}},{"id":1290583,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-30T22:20:46.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":155000,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001578563-25-000026","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856325000026/primary_doc.xml","form_type":"4"}},{"id":1453535,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-16T20:23:55.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":234000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Option Shares vest on July 15, 2025 and the remainder of the Option Shares will vest in equal monthly installments over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date."}],"balance_after":234000,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":234000},"source":{"system":"sec-edgar","filing":"0001578563-24-000331","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856324000331/primary_doc.xml","form_type":"4"}},{"id":1811661,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-09T16:21:24.000Z","date":"2023-08-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\") entered into the Agreement and Plan of Merger (the \"Merger Agreement\"), with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the \"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 9, 2023, each share of the Company's Common Stock,\npar value $0.0001 per share (\"Common Stock\"), was either (x) purchased for $48.00 per share (the \"Offer Price\"), without interest, less any\napplicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price,\nless any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the\nCommon Stock fully lapsed and all Common Stock became fully vested."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\"), became fully vested and exercisable (the \"Vested Option\").  Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Company's Stock Option (the \"Option\") vests as to 1/36th of the total shares on each monthly anniversary of March 31, 2022, subject to the Reporting Holder's continued service to the Registrant."}],"balance_after":0,"derivative":{"exercise_price":19.13,"expiration_date":"2032-03-31","underlying":"Common Stock","underlying_shares":42500},"source":{"system":"sec-edgar","filing":"0001209191-23-045170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645569/000120919123045170/doc4.xml","form_type":"4"}},{"id":2310695,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-01T18:27:04.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/36th of the total shares on each monthly anniversary of March 31, 2022, subject to the Reporting Holder's continued service to the Registrant."}],"balance_after":42500,"derivative":{"exercise_price":19.13,"expiration_date":"2032-03-31","underlying":"Common Stock","underlying_shares":42500},"source":{"system":"sec-edgar","filing":"0001209191-22-022056","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645569/000120919122022056/doc4.xml","form_type":"4"}}]}